Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited

• Sverre E. Kjeldsen,
• Krzysztof Narkiewicz,
• Michel Burnier,
• Suzanne Oparil

Affiliations

Sverre E. Kjeldsen

University of Oslo, Ullevaal Hospital

Krzysztof Narkiewicz

Medical University of Gdansk

Michel Burnier

Centre Hospitalier Universitaire Vaudois

Suzanne Oparil

University of Alabama at Birmingham